Company
Eve Health Group Ltd
ASX:EVE
Eve Health Group is an Australian life sciences company developing improved formulations of established pharmaceutical compounds to enhance therapeutic outcomes for patients.
11 stories
THC Global Group’s second manufacturing licence opens door to product development
This follows the manufacturing licence granted in June 2019 for its Bundaberg facility.
THC Global's new manufacturing licence a boost for cannabis honey products
Eve Investments, via agreements with THC Global, now has a viable option to access THC’s cannabis licensing for research and development of its products.
THC Global shares rise after securing medicinal cannabis export licence
The company is also expanding the total leased land for its Northern NSW cannabis cultivation site up to 150,000 square metres.
The Hydroponics Company to lease land for growing medicinal cannabis
The new agreements have synergies with the recent biomanufacturing facility acquisition.
EVE Investments seeing momentum for pre-meal drink in China
The company has two investment partners, Meluka Honey and Omni Innovation.
Eve Investments targets US$40 billion medical nutrition market as Meluka Honey gains traction
Annual honey production of 100 tonnes per year is being targeted within the next 12 months.
Eve Investments and Queensland Bauxite are the ASX Most Active but head south
Eve Investments has traded over $9 million of stock by noon.
EVE Investments tops the ASX Most Active on hemp leverage
EVE Investments is a five-bagger in just the past month.
Refresh Group acquires Sydney-based bottled water supplier
The company’s operations achieved record profits in FY2016.
Refresh Group is looking beyond distilled drinking water
Refresh Group (ASX:RGP) has taken up a $300,000 placement of shares in Eve Investments (ASX:EVE), an investment company focused on the technology sector, at $0.008 per share.